One of the key differentiators of Probuphine is its utilization of Titan's proprietary drug delivery system, ProNeura™, capable of sustaining consistent levels of medication for up to 12 months. This technology not only demonstrates its efficacy in opioid dependence treatment but also holds potential for addressing other chronic conditions such as Parkinson's disease and hypothyroidism. The ability to maintain consistent, around-the-clock blood levels of medication has the potential to significantly benefit patients and enhance medical outcomes. Despite the lack of recent disclosed investments, Titan Pharmaceuticals' advancements in revolutionary drug delivery technologies and its commitment to improving patient care position it as a compelling prospect within the pharmaceutical industry for potential investors.
Titan Pharmaceuticals
South San Francisco, United States
33 employees
Post-IPO Equity
Total: $54.20M
Biotechnology, Health and Wellness
General Information
South San Francisco, United States
BounceWatch is an independent company data service, not affiliated with Titan Pharmaceuticals. To contact Titan Pharmaceuticals, visit titanpharm.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Titan Pharmaceuticals compare?
A PDF of Titan Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Titan Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Titan Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Titan Pharmaceuticals
Business keywords: biopharmaceutical, drug delivery system, opioid dependence treatment, FDA approval, continuous blood levels, ProNeura technology, sustained medication delivery, Braeburn Pharmaceuticals partnership, probuphine, chronic conditions treatment, Parkinson's disease, hypothyroidism, medical outcomes, proprietary therapeutics, commercialization
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | Undisclosed | 1 |
|
25 Oct 2021 |
| Post IPO Equity | $9.70M | - |
|
15 Jan 2021 |
| Post IPO Equity | $9.50M | - |
|
20 Sep 2018 |
| Post IPO Debt | $10.00M | 1 |
|
27 Jul 2017 |
| Post IPO Equity | $5.00M | - |
|
13 Nov 2013 |
| Post IPO Debt | $20.00M | 1 |
Deerfield
|
16 Mar 2011 |
Titan Pharmaceuticals Alternatives & Competitors
View All Alternatives
We discover and develop novel therapeutics for patients living with inflammatory and autoimmune cond...
We have the next generation in polymer therapeutics. Go to www.serinatherapeutics.com and explore ou...
Advanced Catheter Therapies ("ACT") is a commercialization stage medical device company with a targe...
Lyra Therapeutics
FAQ About Titan Pharmaceuticals
Source: BounceWatch company record for Titan Pharmaceuticals, https://bouncewatch.com/company/titan-pharmaceuticals, updated 29 November 2024. When citing, please name BounceWatch and link this page.
